Jeffrey M. Jonas - Feb 17, 2022 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Innovation Officer, Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Stock symbol
SAGE
Transactions as of
Feb 17, 2022
Transactions value $
$1,800
Form type
4
Date filed
2/18/2022, 03:10 PM
Previous filing
Feb 15, 2022
Next filing
Apr 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Options Exercise $1.8K +4K +4.95% $0.45* 84.9K Feb 17, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Options Exercise $0 -4K -8.59% $0.00 42.6K Feb 17, 2022 Common Stock 4K $0.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017.